Get the latest news, insights, and market updates on ACRS (Aclaris Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
3 Promising Penny Stocks With A Market Cap Below $400M
As the holiday-shortened week begins, major U.S. stock indexes have dipped, with technology shares leading the decline and precious metals retreating from recent highs. In such a fluctuating market landscape, identifying stocks with potential for growth can be challenging but rewarding. Penny stocks, often associated with smaller or emerging companies, continue to offer intriguing opportunities for investors willing to explore beyond traditional blue-chip options. These stocks can provide... Dec 30, 2025 - $ACRS
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)
WAYNE, Pa., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading today, December 19, 2025. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® that are classified as either biotechnolo Dec 19, 2025 - $ACRS
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
WAYNE, Pa., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Aclaris’ Chief Executive Officer and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Piper Sandler 37th Annual Healthcare Conference in New York City. The discussion will take place on Tuesday December Nov 25, 2025 - $ACRS
Discovering Aclaris Therapeutics And Two Other Noteworthy Penny Stocks
With major U.S. stock indexes recently snapping a four-session skid, investors are keeping a close eye on market movements and upcoming economic reports. In this context, penny stocks—though an older term—continue to capture interest as they often represent smaller or emerging companies with potential for growth. By focusing on those with strong financial health, investors can uncover opportunities in these lesser-known stocks that might offer both stability and potential upside. Nov 20, 2025 - $ACRS
Aclaris: Q3 Earnings Snapshot
WAYNE, Pa. AP) — Aclaris Therapeutics Inc. ACRS) on Thursday reported a loss of $14.6 million in its third quarter. Nov 6, 2025 - $ACRS
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Positive Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, Further Validating ITK as Therapeutic Target; Initiation of Phase 2 Trial in an Additional Indication Expected in the First Half of 2026 - - Timelines Reiterated for Top Line Clinical Results from Ongoing Trials of Investigational Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) and Anti-TSLP/IL-4R Bispecific Antibody ATI-052 - - Initiation Nov 6, 2025 - $ACRS
Aclaris Therapeutics to Participate in Three November Healthcare Conferences
WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in three upcoming healthcare conferences in November. On Wednesday November 12, 2025, at 11:00 AM EST, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside c Oct 29, 2025 - $ACRS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple